GSC The List

Post Reply
Forum Home > S > SPASTICITY*+

[email protected]
Site Owner
Posts: 1174

New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids (full - 2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835560/?tool=pmcentrez

Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis (abst – 2010) http://msj.sagepub.com/cgi/content/abstract/16/6/707?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=cannabis&searchid=1&FIRSTINDEX=0&sortspec=date&resourcetype=HWCIT

Role of cannabinoids in the treatment of pain and (painful) spasticity. (abst – 2010) http://www.ncbi.nlm.nih.gov/pubmed/21142261

Dronabinol for the treatment of unspecific pain, restlessness and spasticity in neuropaediatrics (abst – 2010) https://www.thieme-connect.com/ejournals/abstract/10.1055/s-0030-1265622

Emerging treatment options for spasticity in multiple sclerosis; clinical utility of cannabinoids (link to PDF – 2011) http://www.dovepress.com/articles.php?article_id=7675

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis (abst – 2011) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=322

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis (abst - 2011) http://www.unboundmedicine.com/medline/ebm/record/21456949/abstract/THC_and_CBD_oromucosal_spray__Sativex%C2%AE__in_the_management_of_spasticity_associated_with_multiple_sclerosis_

Cannabinoids in children (abst – 2011) http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=295

The Therapeutic Potential of Cannabis and Cannabinoids (full – 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442177/

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols) (full – 2012) http://msj.sagepub.com/content/18/2/219.long

Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis. (full – 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423911/pdf/ISRN.NEUROLOGY2012-802649.pdf

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial (full – 2012) http://www.cmaj.ca/content/184/10/1143.long

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity (full – 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437528/

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22509985

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22954177

What place for cannabis extract in MS? (abst – 2012) http://dtb.bmj.com/content/50/12/141.abstract

Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/23011861

Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis. (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/23072659

Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/23011861?dopt=Abstract

Smoked Cannabis Reduces Some Symptoms of Multiple Sclerosis (news – 2012) http://health.ucsd.edu/news/releases/Pages/2012-05-14-smoked-cannabis-reduces-symptoms-of-multiple-sclerosis.aspx

Cannabis as Painkiller (news – 2012) http://www.sciencedaily.com/releases/2012/08/120807101232.htm

Clinical experiences with cannabinoids in spasticity management in multiple sclerosis (full – 2013) http://zl.elsevier.es/en/revista/neurologia-495/articulo/clinical-experiences-with-cannabinoids-in-90328787

Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23369054

Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/22726074

A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23369055

Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23625705

Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24121462

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/22878432

Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24289844

Who Benefits Most from THC:CBD Spray? Learning from Clinical Experience (full – 2014) http://www.karger.com/Article/FullText/357743

THC:CBD Spray and MS Spasticity Symptoms: Data from Latest Studies (full – 2014) http://www.karger.com/Article/FullText/357742

Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis related spasticity. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24392812

Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24525548

Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24671907

Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24943098

Delta-9-tetrahydrocannabinol + cannabidiol. A reasonable option for some patients with multiple sclerosis. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25121144

Discriminating the effects of Cannabis sativa and Cannabis indica: a web survey of medical cannabis users. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25191852

Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways. (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25278116

Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25331416

There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25350886

Complementary and alternative medical therapies in multiple sclerosis-the american academy of neurology guidelines: a commentary (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25467189

"Disease Modifying Nutricals" for multiple sclerosis (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25435020

Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation (full – 2015) http://www.hindawi.com/journals/np/2015/656582/

Drug-resistant MS spasticity treatment with Sativex® add-on and driving ability (full – 2015) http://onlinelibrary.wiley.com/doi/10.1111/ane.12287/full

March 28, 2015 at 6:22 AM Flag Quote & Reply

This topic is closed, no additional posts are allowed.